Both the primary tumor and the pulmonary metastasis harbored a missense mutation in the start codon (p.M1V) of BRIP1. Whereas in February 2018 no therapeutic option was indicated, the NGS report from July 2019 recommended off-label treatment with olaparib, which had by then been approved for metastatic breast cancer. Here, BRIP1 is linked to neoplasm.